• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Food & Drug Administration (FDA)

Bayer wins FDA nod for connected MS auto-injector

May 31, 2017 By Sarah Faulkner

Bayer BetaConnect auto-injector

Bayer (ETR:BAYN) said yesterday that the FDA approved a supplemental biologics license application for the BetaConnect Navigator and myBetaApp – software for its electronic BetaConnect auto-injector. The company’s BetaConnect auto-injector administers Betaseron for patients with relapsing-remitting multiple sclerosis. The newly-approved software allows patients to connect their device with the myBetaApp on their mobile device or computer […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Regulatory/Compliance, Wall Street Beat Tagged With: Bayer AG

Novo Nordisk seeks to include cardiovascular data in Tresiba insulin label

May 30, 2017 By Sarah Faulkner

Novo Nordisk

Novo Nordisk (NYSE:NVO) said today that it submitted a supplemental application to the FDA, asking to include cardiovascular data on the label of its Tresiba insulin degludec. The Danish insulin-maker asked to include data specifically from the Devote trial, which evaluated the cardiovascular safety of Tresiba compared to insulin glargine in patients with Type II diabetes. The […]

Filed Under: Cardiovascular, Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Novo Nordisk

FDA deals setback to Sunovion for inhaled COPD therapy

May 30, 2017 By Sarah Faulkner

Sunovion Pharmaceuticals

The FDA issued a complete response letter to Sunovion Pharmaceuticals in regards to the new drug application for its eFlow chronic obstructive pulmonary disease drug-device combo. The investigational eFlow closed-system nebulizer delivers a long-acting muscarinic antagonist bronchodilator, glycopyrrolate, to reduce airflow obstruction in COPD patients. The company said it plans to work with the FDA to determine […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory Tagged With: Sunovion Pharmaceuticals

FDA cybersecurity workshop offers long-term solutions for medical device sector

May 30, 2017 By Danielle Kirsh

By Stewart Eisenhart, Emergo Group The US Food and Drug Administration’s latest workshop on medical device cybersecurity issues, held May 18 and 19, 2017, firmly established myriad challenges in mitigating this risk, and that no easy or quick fixes are yet available to help manufacturers and other stakeholders address these challenges. Get the full story […]

Filed Under: Food & Drug Administration (FDA) Tagged With: blog, Emergo Group

FDA Commissioner asks staff for ‘more forceful steps’ to stem the opioid crisis

May 26, 2017 By Danielle Kirsh

FDA

By: Scott Gottlieb, M.D. As Commissioner, my highest initial priority is to take immediate steps to reduce the scope of the epidemic of opioid addiction. I believe the Food and Drug Administration continues to have an important role to play in addressing this crisis, particularly when it comes to reducing the number of new cases […]

Filed Under: Food & Drug Administration (FDA) Tagged With: blog, FDA Voice

FDA chief: Changing generics regulations could reel in drug prices

May 25, 2017 By Sarah Faulkner

FDA

Part of the FDA commissioner’s job is to oversee the federal regulatory watchdog as it evaluates pharmaceuticals for safety and efficacy. Most FDA chiefs have avoided the topic of drug prices, given that it isn’t a clearly-stated part of the agency’s mission But just 2 weeks into the job, newly-confirmed FDA commish Dr. Scott Gottlieb proposed […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy Tagged With: Mylan

BioCorRx to meet with the FDA for injectable, sustained-release opioid addiction therapy

May 25, 2017 By Sarah Faulkner

BioCorRx

BioCorRx (OTC:BICX) said today that the FDA has granted the anti-addiction developer a pre-investigational new drug meeting, scheduled for Sept. 19. The Anaheim, Calif.-based company said it is slated to review the development and marketing plan for BICX101, an injectable, sustained-release formulation of naltrexone as a therapy for opioid addiction and alcohol use disorders. At […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: BioCorRx

FDA approves 1st cancer drug based on genetics, not tissue type

May 24, 2017 By Sarah Faulkner

Merck

In a landmark decision, the FDA approved Merck‘s (NYSE:MRK) immunotherapy Keytruda yesterday as the 1st cancer treatment indicated for any solid tumor with a specific genetic feature, regardless of tissue type. Traditionally, the location where a cancer originates in a patient’s body determines the course of treatment. The move to treat cancers based on genetic biomarkers […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Merck

FDA launches medical device cybersecurity workshop

May 24, 2017 By Danielle Kirsh

By Stewart Eisenhart, Emergo Group Effectiveness of ongoing efforts to address medical device cybersecurity risks will depend on whether stakeholders can properly balance security, safety and usability issues as well as understand end-user environments, according to speakers at a new US Food and Drug Administration workshop. Get the full story here at the Emergo Group’s […]

Filed Under: Food & Drug Administration (FDA) Tagged With: blog, Emergo Group

Trump proposes deep cuts to Medicaid, NIH funding

May 23, 2017 By Sarah Faulkner

Capitol Hill

President Donald Trump’s proposed budget would slash Medicaid funding and cut support for major biomedical research programs at the National Institutes of Health and the Centers for Disease Control & Prevention. The budget blueprint drew condemnation from healthcare advocates and lawmakers from both sides of the aisle. Senate majority whip Sen. John Cornyn (R-Texas) reportedly said earlier […]

Filed Under: Featured, Food & Drug Administration (FDA), Funding Roundup, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Centers for Medicare and Medicaid Services (CMS), National Institutes of Health

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 78
  • Page 79
  • Page 80
  • Page 81
  • Page 82
  • Interim pages omitted …
  • Page 95
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS